Endpoints News
Meet Lilly's regenerative medicine chief Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Th Fri
6 March, 2026
Drug Discovery Day 2026
AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.
presented by TrialWire
The $50K-a-day prob­lem in clin­i­cal tri­al en­roll­ment
SPOTLIGHT
In Focus
Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans
ENDPOINTS NEWS
news
As FDA decisions get harder to predict, top official blasts outside advisory panels
ENDPOINTS NEWS
Updated: Zealand’s stock plummets on Phase 2 obesity data for Roche-partnered amylin drug
ENDPOINTS NEWS
Peer Review
Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
ENDPOINTS NEWS
Endpoints webinars
Mar 24
11:30 am ET
From structure to selectivity: Federated AI for collaborative binding affinity prediction
Rhino Federated Computing
ONCOLOGY INDUSTRY PARTNERING EVENT FROM CANCER DISCOVERIES TO PATIENTS
Register to see thought-leaders across pharma and biotech present innovation strategies for drug development and new partnership and licensing opportunities to advance these concepts.
sponsored by American Association for Cancer Research
ENDPOINTS PHARMA
Kura says its menin inhibitor is preferred treatment for a 'handful' of payers
ENDPOINTS NEWS
The $100 genome, both a scientific milestone and marketing tool, is here
ENDPOINTS NEWS
FDA approves J&J's multiple myeloma combo as second-line treatment
ENDPOINTS NEWS
New FDA bonuses for faster reviews meant to help address ‘critical workforce challenges’
ENDPOINTS NEWS
Eli Lilly's new program aims to boost employer coverage of GLP-1s
ENDPOINTS NEWS
in case you missed it
1.
Helus Pharma's stock slides after psychedelic drug data face questions over dosing
ENDPOINTS NEWS
2.
Tenaya wins support from Alnylam in cardio disease pact
ENDPOINTS NEWS
3.
Merck KGaA drops two cancer trials on assets from SpringWorks deal
ENDPOINTS NEWS
4.
FDA puts PepGen’s Phase 2 muscle disease trial on partial hold
ENDPOINTS NEWS
5.
Johnson & Johnson units to pay $65 million to settle Tracleer antitrust class action
REUTERS
Elizabeth Cairns
.

A senior FDA official has suggested that FDA advisory committees might not be all they're cracked up to be. Speaking with reporters, including Endpoints' Max Bayer, the person said that these panel meetings use “pomp and flash instead of scientific truth.” Read Max's analysis here, and have a great weekend.

.
Elizabeth Cairns
Senior Biopharma Journalist, Endpoints News